👀 Ones to watch: Undervalued stocks to buy before they report Q3 earningsSee Undervalued Stocks

Can Rite Aid's (RAD) Reverse Stock Split Plan Aid Stock?

Published 01/28/2019, 06:55 AM
Updated 07/09/2023, 06:31 AM
ANF
-
WBA
-
US90274J5618=UBSS
-
DBI
-

Responding to the letter from the New York Stock Exchange (“NYSE”) regarding share price rules and its non-compliance for listing, Rite Aid Corporation’s (NYSE:RAD) board proposed a reverse split of its common stock. This will help the company regain full compliance with NYSE’s listing rules. However, the reverse stock split still awaits shareholder approval.

The company will hold a Special Meeting of Stockholders on March 21, 2019, where shareholders will vote for the approval and adoption of the reverse stock split. The record date for stockholders’ eligibility to vote for the split is set on Feb 5.

The stock split, if approved, will allow the board to select from proposed reverse stock split ratios of 1-for-10, 1-for-15 or 1-for-20. As a result, depending on the chosen ratio, either 10, 15 or 20 of the company’s outstanding or issued common shares will be converted into one share. Consequently, there will be a price increase of each common stock. This will mean that shareholders will have fewer shares but those will be priced higher. However, the stock split will not alter stockholders’ voting and other rights. It also will not impact the company’s operations or debt position.

Despite shareholders’ approval, the company’s board retains the right to abandon the reverse stock split at any time, in case the split is found to no longer benefit the company or its shareholders.

Rite Aid has been witnessing ups and downs in the recent past, given two failed mergers with Walgreens (NASDAQ:WBA) and Albertsons, and other operational issues. The company’s lower stock led to non-compliance of listing rules of NYSE. Rite Aid may regain compliance under the NYSE listing rules, if its share price is at least $1.00 and it maintains average closing price of at least $1.00 in the past 30 trading days during the six-month cure period or on Jul 3, 2019 — the end of the six-month cure period. Until then, the company’s shares will be listed and continue to trade on the NYSE.

Notably, Rite Aid’s shares have lost 57.3% in the past year, significantly wider than the industry’s decline of 16.5%.



Despite margin woes and a soft outlook, Rite Aid is bracing up for growth by leveraging retail pharmacies, EnvisionRxOptions PBM, and health and wellness offerings. Rite Aid expects to maintain the earnings momentum by enhancing clinical services in the pharmacy business, boosting customer experience, and investing in retail and pharmacy services businesses. However, it remains to be seen how this Zacks Rank #3 (Hold) company’s strategies play out.

Interested in Retail Space? Check These

Investors can count on some better-ranked stocks like Abercrombie & Fitch Company (NYSE:ANF) and DSW Inc. (NYSE:DSW) , both carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Abercrombie & Fitch has a long-term earnings growth rate of 15.3%. Further, the stock has surged 8.5% in the past three months.

DSW has rallied 28.4% in a year and has a long-term earnings growth rate of 9%.

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>



Abercrombie & Fitch Company (ANF): Free Stock Analysis Report

DSW Inc. (DSW): Get Free Report

Walgreens Boots Alliance, Inc. (WBA): Get Free Report

Rite Aid Corporation (RAD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.